Search results
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 2 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 52 minutes agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 22 hours agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 22 hours agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 2 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 26 minutes agoPharma giant Pfizer Inc. (NYSE: PFE) announced on Wednesday after markets closed that its gene...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 21 hours agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 1 day agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 7 hours agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 1 day agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...